ADIL on Nasdaq
ADIAL PHARMACEUTICALS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Research and development | $2.6M | $3.2M | |
| General and administrative | $5.2M | $5.1M | |
| Total Operating Expenses | $7.8M | $8.3M | |
| Loss From Operations | -$7.8M | -$8.3M | |
| Interest income | $149.6K | $178.7K | |
| Inducement expense | -$4.5M | ||
| Loss on equity method investment | -$492.1K | $492.1K | -$552.2K |
| Other income (expense) | $164.9K | -$75.0K | |
| Total other Income (Expense) | -$177.7K | -$4.9M | |
| Net Loss | -$8.0M | -$13.2M | |
| Loss per share, basic (in Dollars per share) | -$11.93 | -$68.01 | |
| Loss per share, diluted (in Dollars per share) | -$11.93 | -$68.01 | |
| Weighted average shares, basic (in Shares) | 668.6K shares | 194.1K shares | |
| Weighted average shares, diluted (in Shares) | 668.6K shares | 194.1K shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $5.9M | $3.8M | |
| Prepaid expenses and other current assets | $299.7K | $308.2K | |
| Total Current Assets | $6.2M | $4.1M | |
| Intangible assets, net | $2.8K | $3.3K | |
| Equity method investment | $489.7K | $981.8K | |
| Total Assets | $6.7M | $5.0M | |
| Accounts payable | $655.2K | $250.1K | |
| Accrued expenses | $741.7K | $677.5K | |
| Total Current Liabilities | $1.4M | $975.9K | |
| Total Liabilities | $1.4M | $975.9K | |
| Common Stock, 100,000,000 shares authorized with a par value of $0.001 per share, 1,111,124 and 258,940 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1.1K | $259 | |
| Additional paid in capital | $95.2M | $86.1M | |
| Accumulated deficit | -$90.0M | -$82.0M | |
| Total Stockholders Equity | $5.3M | $4.1M | $4.1M |
| Total Liabilities and Stockholders Equity | $6.7M | $5.0M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 5.0M shares | 5.0M shares | |
| Preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares Outstanding (in Shares) | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 1.1M shares | 258.8K shares | |
| Common stock, shares Outstanding (in Shares) | 1.1M shares | 258.8K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|
| Loss from operations | -$8.0M | -$13.2M | |
| Stock-based compensation | $676.2K | $796.8K | |
| Amortization of intangible assets | $565 | $565 | |
| Inducement expense | $4.5M | ||
| Cost of commitment shares issued | $75.0K | ||
| Change in fair value contingent consideration | -$150.0K | ||
| Loss on equity method investment | $492.1K | -$492.1K | $552.2K |
| Prepaid expenses and other current assets | $8.6K | $63.4K | |
| Accrued expenses | $100.3K | $199.7K | |
| Accrued expenses, related party | -$47.9K | ||
| Accounts payable and other current liabilities | $405.1K | $146.8K | |
| Accounts payable, related party | -$48.3K | $24.2K | |
| Net cash used in operating activities | -$6.5M | -$6.9M | |
| Cash receipt from contingent consideration | $150.0K | ||
| Net cash provided by investing activities | $150.0K | ||
| Net proceeds from sale of common stock | $3.7M | $4.0M | |
| Proceeds from warrant exercise, net of expenses | $4.8M | $3.8M | |
| Net cash provided by financing activities | $8.5M | $7.8M | |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | $2.1M | $923.4K | |
| Issuance of common stock to settle bonus accrual | $36.0K |
Former names
- Adial Pharmaceuticals, L.L.C.May 12, 2017 to Sep 28, 20172
Recent filings
- Oct 5, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS
- Oct 2, 20268-K CURRENT REPORT
- Sep 21, 20264
- Sep 18, 20268-K CURRENT REPORT
- Sep 18, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS
- Sep 16, 20268-K CURRENT REPORT
- Sep 16, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS
- Aug 28, 2026S-8 REGISTRATION STATEMENT
- Aug 28, 2026S-3 REGISTRATION STATEMENT
- Aug 25, 20268-K CURRENT REPORT
- Aug 24, 2026DEF 14A PROXY STATEMENT
- Aug 24, 2026ARS
- Aug 21, 20268-K CURRENT REPORT
- Aug 17, 20268-K CURRENT REPORT
- Aug 14, 202610-Q QUARTERLY REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10